-
2022-502154-13-00
5
2023-10-27
Patients with well to moderately differentiated neuroendocrine tumors
-
2022-502082-22-00
11
2023-09-14
prediabetes
-
2022-501831-18-00
4
2023-09-13
Patients with hematologic malignancies and undergoing allogenic hemato
-
2023-504709-35-00
1
2023-08-16
Locally advanced or metastatic solid tumors
-
2022-502703-30-00
6
2023-06-28
neuroendocrine tumours
-
2022-501943-34-00
5
2023-06-27
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
-
2022-501780-41-00
5
2023-05-17
Irritable Bowel Syndrome
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2023-509046-36-00
5
2023-04-26
Active Ulcerative Colitis (UC) or Crohn's disease (CD)
-
2023-504897-39-00
1
2023-04-13
Advanced or refractory solid tumours (Part 1)
-
2023-508644-22-00
7
2023-02-28
Advance Solid Tumors
-
2024-515293-27-00
4
2023-02-24
Malignant pleural mesothelioma, epithelioid subtype (stage I-IV)
-
2022-501181-22-01
4
2023-02-06
Pancreatic adenocarcinoma
-
2023-509672-42-00
5
2023-02-02
GRIN-related neurodevelopmental disorder
-
2022-502140-13-00
6
2023-01-11
Atrial fibrillation
Acute coronary syndrome
Chronic coronary syndrome
-
2023-506239-14-00
5
2022-12-13
Ulcerative Colitis
-
2024-514826-22-00
7
2022-12-05
Part A: Patients with advanced solid tumors or lymphomas.
-
2023-503679-12-00
1
2022-11-21
Relapsed or Refractory Multiple Myeloma
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2024-510990-21-00
10
2022-11-11
Mucopolysaccharidosis Type II [MPS II]
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2024-514266-39-00
7
2022-11-03
Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors wit
-
2022-500311-39-00
6
2022-09-08
Patients with Crohn's disease undergoing surgery and having at least o
-
2023-506517-22-00
9
2022-08-31
Advanced or Metastatic Colorectal Cancer